ASCOT-LLA: questions about the benefits of atorvastatin.
Ravnskov
Uffe
U
D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D000069059:Atorvastatin; D002318:Cardiovascular Diseases / Q000150:complications / Q000517:prevention & control*; D003920:Diabetes Mellitus / Q000209:etiology; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007674:Kidney Diseases / Q000209:etiology; D009369:Neoplasms / Q000139:chemically induced / Q000453:epidemiology; D011758:Pyrroles / Q000627:therapeutic use*
D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin